No Data
No Data
BioAffinity Technologies Sees Accelerating Growth Of Physician Practices Ordering CyPath Lung Tests
Sales of CyPath Lung tests, onboarding of pathology practices ahead of forecastsbioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company focused on the need for noninvasive tests
10-Q: Quarterly report
Express News | BioAffinity Technologies Inc: Qtrly Shr Loss $0.21
Earnings Flash (BIAF) BIOAFFINITY TECHNOLOGIES Posts Q1 Revenue $2.4M
09:17 AM EDT, 05/15/2024 (MT Newswires) -- Earnings Flash (BIAF) BIOAFFINITY TECHNOLOGIES Posts Q1 Revenue $2.4M
Press Release: BioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath(R) Lung Sales and Increased Laboratory Volumes
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today reported financial results for the three months ended March 31, 2024.
Express News | BioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of Cypath® Lung Sales and Increased Laboratory Volumes
No Data